Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
et decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i et » i e (Expand Search), i ex (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
et decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i et » i e (Expand Search), i ex (Expand Search)
-
641
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
642
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
643
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
644
-
645
-
646
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
647
-
648
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
649
-
650
-
651
-
652
-
653
-
654
-
655
-
656
-
657
-
658
-
659
Monofunctional Hyperbranched Ethylene Oligomers
Published 2014“…The neutral κ<sup>2</sup><i>N</i>,<i>O</i>-salicylaldiminato Ni(II) complexes [κ<sup>2</sup><i>N</i>,<i>O</i>-{(2,6-(3′,5′-R<sub>2</sub>C<sub>6</sub>H<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>-NC(H)-(3,5-I<sub>2</sub>-2-O-C<sub>6</sub>H<sub>2</sub>)}]NiCH<sub>3</sub>(pyridine)] (<b>1a-pyr</b>, R = Me; <b>1b-pyr</b>, R = Et; <b>1c-pyr</b>, R = <i>i</i>Pr) convert ethylene to hyperbranched low-molecular-weight oligomers (<i>M</i><sub>n</sub> ca. 1000 g mol<sup>–1</sup>) with high productivities. …”
-
660